Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

被引：3

作者：

Phillips, Tycel ^{[1
]}

Lugtenburg, Pieternella ^{[2
]}

Kalsekar, Anupama ^{[3
]}

Mutebi, Alex ^{[3
]}

Wang, Anthony ^{[4
]}

Blaedel, Julie ^{[3
]}

Kosa, Katherine ^{[5
]}

Martin, Susan ^{[5
]}

Sacchi, Mariana ^{[3
]}

Thieblemont, Catherine ^{[6
,7
]}

机构：

[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI USA

[2] Erasmus MC, Dept Hematol, HOVON Lymphoma Working Grp, Canc Inst,Univ Med Ctr, Rotterdam, Netherlands

[3] Genmab, Princeton, NJ USA

[4] AbbVie Inc, N Chicago, IL USA

[5] RTI Hlth Solut, Ann Arbor, MI USA

[6] Hop St Louis, AP HP, Paris, France

[7] Diderot Univ, Sorbonne Paris Cite, Paris, France

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159544

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：8022 / 8023

页数：2

共 50 条

[1] Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study
Thieblemont, Catherine
Phillips, Tycel
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Do, Young Rok
Feldman, Tatyana
Gasiorowski, Robin
Jurczak, Wojciech
Kim, Tae Min
Lewis, David John
van der Poel, Marjolein
Poon, Michelle Limei
Doerr, Thomas
Kilavuz, Nurgul
Chen, Menghui
Sacchi, Mariana
Elliott, Brian
Hutchings, Martin
Lugtenburg, Pieternella
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S379 - S379
[2] Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial
Catherine, Thieblemont
Tycel, Phillips
Herve, Ghesquieres
Cheah, Chan Y.
David, Cunningham
Do, Young R.
Tatyana, Feldman
Robin, Gasiorowski Robin
Wojciech, Jurczak
Tae, Min Kim Tae M.
Lewis, David J.
Mariolein, Van der Poe
Poon, Michelle L.
Thomas, Doerr
Nurgul, Kilavuz
Menghui, Chen
Mariana, Sacchi
Martin, Hutchings
Pieternella, Lugtenburg
Roost, Clausen Michael
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S32
[3] Subcutaneous Epcoritamab in Patients with Relapsed/ Refractory Large B-Cell Lymphoma: Longer-Term Results From the Pivotal EPCORE NHL-1 Trial
Tatyana, Feldman
Yasmin, Karimi
Herve, Ghesquieres
Wojciech, Jurczak
Chan, Cheah Y.
Michael, Roost Clausen
Pieternella, Lugtenburg
David, Cunningham
Do Young, Rok
John, Lewis David
Robin, Gasiorowski
Min, Kim Tae
Marjolein, van der Poel
Michelle, Limei Poon
Kim, Linton M.
Anna, Sureda
Martin, Hutchings
Mariana, Cota Stirner
Mariana, Sacchi
Catherine, Thieblemont
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S49 - S50
[4] Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data
Izutsu, Koji
Kumode, Takahiro
Yuda, Junichiro
Nagai, Hirokazu
Mishima, Yuko
Suehiro, Youko
Yamamoto, Kazuhito
Fujisaki, Tomoaki
Ishitsuka, Kenji
Ishizawa, Kenichi
Ikezoe, Takayuki
Nishikori, Momoko
Akahane, Daigo
Fujita, Jiro
Wu, Jun
Broberg, Per
Buchbjerg, Jeppe
Fukuhara, Noriko
ANNALS OF ONCOLOGY, 2023, 34 : S1389 - S1389
[5] Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5
Mazza, Irit Avivi
Kim, Won Seog
Ko, Shen
Grande, Carlos
Lavie, David
Chism, David
Seliem, Mostafa
Jeng, Edwin E.
Joshi, Neha
Siddani, Satya
Assaily, Wissam
Sacchi, Mariana
Dinh, Minh
Avigdor, Abraham
BLOOD, 2023, 142
[6] Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
Thieblemont, Catherine
Karimi, Yasmin H.
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Jurczak, Wojciech
Do, Young Rok
Gasiorowski, Robin
Lewis, David John
Kim, Tae Min
van der Poel, Marjolein
Poon, Michelle Limei
Feldman, Tatyana
Linton, Kim M.
Sureda, Anna
Hutchings, Martin
Dinh, Minh H.
Kilavuz, Nurgul
Soong, David
Mark, Thomas
Sacchi, Mariana
Phillips, Tycel
Lugtenburg, Pieternella J.
LEUKEMIA, 2024, : 2653 - 2662
[7] Subcutaneous epcoritamab induces durable complete remissions in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: long-term results from the EPCORE NHL-1 Phase 2 expansion cohort
Scholz, C. W.
Karimi, Y.
Ghesquieres, H.
Jurczak, W.
Cheah, C. Y.
Clausen, M. R.
Lugtenburg, P.
Cunningham, D.
Do, Y. R.
Lewis, D. J.
Gasiorowski, R.
Kim, T. M.
van der Poel, M.
Poon, M. L.
Feldman, T.
Linton, K. M.
Sureda, A.
Hutchings, M.
Stirner, Cota M.
Liu, Y.
Kilavuz, N.
Sacchi, M.
Thieblemont, C.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 268 - 269
[8] IN AND OUT: THE CONVENIENCE OF SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Barnhizer, Tiffanie
Phillips, Tycel
Feldman, Tatyana
Doerr, Thomas
Sacchi, Mariana
Magarelli, Gabriella
ONCOLOGY NURSING FORUM, 2023, 50 (02)
[9] Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab
Phillips, Tycel
Lugtenburg, Pieternella
Kalsekar, Anupama
Mutebi, Alex
Wang, Anthony
Blaedel, Julie
Kosa, Katherine
Martin, Susan
Sacchi, Mariana
Kilavuz, Nurgul
Thieblemont, Catherine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : e78 - e87.e2
[10] Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)
Karimi, Yasmin
Thieblemont, Catherine
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Jurczak, Wojciech
Linton, Kim M.
Hutchings, Martin
Phillips, Tycel Jovelle
Farooq, Umar
Kim, Won Seog
Dinh, Minh H.
Ghosh, Jagannath
Pallai, Rajash
Wielgos-Bonvallet, Monica
Eskelund, Christian
Lugtenburg, Pieternella
Vose, Julie
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →